Evidence map›Paper›PMID 36615909›Full record

ArticleNutrients2023

Ex Vivo Evaluation of Glutamine Treatment in Sepsis and Trauma in a Human Peripheral Blood Mononuclear Cells Model.

Efrossini Briassouli, Marianna Tzanoudaki, Dimitris Goukos, Kostas Vardas, Panagiotis Briassoulis, Stavroula Ilia, Maria Kanariou, Christina Routsi, Serafim Nanas, George L Daikos and 1 more

Open access · goldAbstract read
In one paragraph

Article in Nutrients, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.2field-weighted citation impact, top 56% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 1 citations in OpenAlex.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 3 institutions in 1 country.

Efrossini BriassouliDepartment of Immunology-Histocompatibility, Specialized Center & Referral Center for Primary Immunodeficiencies-Paediatric Immunology, "Aghia Sophia" Children's Hospital, 11527 Athens, Greece.ORCID 0000-0002-9766-8968
Marianna TzanoudakiDepartment of Immunology-Histocompatibility, Specialized Center & Referral Center for Primary Immunodeficiencies-Paediatric Immunology, "Aghia Sophia" Children's Hospital, 11527 Athens, Greece.ORCID 0000-0001-9630-142X
Dimitris GoukosFirst Department of Propaedeutic Medicine, School of Medicine, National and Kapodistrian University of Athens (NKUA), 11527 Athens, Greece.
Kostas VardasFirst Critical Care Department, Evangelismos Hospital, School of Medicine, National and Kapodistrian University of Athens (NKUA), 15772 Athens, Greece.
Panagiotis BriassoulisAttikon University Hospital, School of Medicine, National and Kapodistrian University of Athens (NKUA), 12462 Athens, Greece.ORCID 0000-0002-9789-9002
Stavroula IliaPediatric Intensive Care Unit, University Hospital, School of Medicine, University of Crete, 71110 Heraklion, Greece.ORCID 0000-0002-0936-368X
Maria KanariouDepartment of Immunology-Histocompatibility, Specialized Center & Referral Center for Primary Immunodeficiencies-Paediatric Immunology, "Aghia Sophia" Children's Hospital, 11527 Athens, Greece.
Christina RoutsiFirst Critical Care Department, Evangelismos Hospital, School of Medicine, National and Kapodistrian University of Athens (NKUA), 15772 Athens, Greece.
Serafim NanasFirst Critical Care Department, Evangelismos Hospital, School of Medicine, National and Kapodistrian University of Athens (NKUA), 15772 Athens, Greece.
George L DaikosFirst Department of Propaedeutic Medicine, School of Medicine, National and Kapodistrian University of Athens (NKUA), 11527 Athens, Greece.
George BriassoulisPediatric Intensive Care Unit, University Hospital, School of Medicine, University of Crete, 71110 Heraklion, Greece.ORCID 0000-0003-0928-6183
National and Kapodistrian University of Athens · GRUniversity of Crete · GRChildren's Hospital Agia Sophia · GR

Funding

European Union (European Social Fund (ESF)Operational Program "Education and Lifelong Learning" of the National Strategic Reference Framework (NSRF) Research Funding Program, THALES
6 · The paper itself

Abstract

We aimed to assess the lipopolysaccharide (LPS), or heat shock (HS) induction, and glutamine-modulating effects on heat shock protein-90α (HSP90α) and cytokines in an ex vivo model using peripheral blood mononuclear cells (PBMCs). The PBMCs of patients with septic shock, trauma-related systemic inflammatory response syndrome (SIRS), and healthy subjects were incubated with 1 μg/mL LPS at 43 °C (HS). Glutamine 10 mM was added 1 hour before or after induction or not at all. We measured mRNA HSP90α, monocyte (m) and lymphocyte (l) HSP90α proteins, interleukin (IL)-1b, -6, -8, -10, tumor necrosis factor-α (TNF-α), and monocyte chemoattractant protein-1 (MCP-1) supernatant levels. Heat shock increased the HSP90α mRNA and mHSP90α in all groups (10-fold in sepsis, p < 0.001 and p = 0.047, respectively). LPS induced the mHSP90α and lHSP90α in healthy (p < 0.001) and mHSP90α in SIRS (p = 0.004) but not in sepsis. LPS induced the cytokines at 24 and 48 h in all groups, especially in trauma (p < 0.001); HS only induced the IL-8 in healthy (p = 0.003) and septic subjects (p = 0.05). Glutamine at 10 mM before or after stimulation did not alter any induction effect of LPS or HS on HSP90α mRNA and mHSP90α protein in sepsis. In SIRS, glutamine before LPS decreased the mHSP90α but increased it when given after HS (p = 0.018). Before or after LPS (p = 0.049) and before HS (p = 0.018), glutamine decreased the lHSP90α expression in sepsis but increased it in SIRS when given after HS (p = 0.003). Regarding cytokines, glutamine enhanced the LPS-induced MCP-1 at 48 h in healthy (p = 0.011), SIRS (p < 0.001), and sepsis (p = 0.006). In conclusion, glutamine at 10 mM, before or after LPS and HS, modulates mHSP90α and lHSP90α in sepsis and SIRS differently and unpredictably. Although it does not alter the stimulation effect on interleukins, glutamine enhances the LPS induction effect on supernatant MCP-1 in all groups. Future research should seek to elucidate better the impact of glutamine and temperature modulation on HSP90α and MCP-1 pathways in sepsis and trauma.

Indexed as

Leukocytes, MononuclearSepsisCytokinesGlutamineHeat-Shock ProteinsHumansInterleukinsLipopolysaccharidesRNA, MessengerSystemic Inflammatory Response SyndromeTumor Necrosis Factor-alphaCytokinesGlutamineHeat-Shock ProteinsInterleukinsLipopolysaccharidesRNA, MessengerTumor Necrosis Factor-alphacritically illcytokinesflow cytometryglutamineheat shockheat shock proteininterleukinlipopolysaccharideMCP-1mRNAperipheral blood mononuclear cellssepsistrauma

Identifiers

PMID36615909
PMCPMC9824313
OpenAlexW4313584200

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.